Nanomedicine News

RSS

Novavax Begins Enrollment in RSV Vaccine Phase 2 Dose-Confirmatory Clinical Trial

Novavax, Inc. today announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.

From Novavax Inc. 8 Oct 2013

Mammalian Cells Prefer Disc-Shaped Rather Than Rod-Shaped Nanoparticles

For years scientists have been working to fundamentally understand how nanoparticles move throughout the human body. One big unanswered question is how the shape of nanoparticles affects their entry into cells. Now researchers have discovered that under typical culture conditions, mammalian cells prefer disc-shaped nanoparticles over those shaped like rods.

From Georgia Institute of Technology 8 Oct 2013

Tekmira Presents Additional TKM-PLK1 Data at 6th Annual NET Conference

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today announced that it presented additional TKM-PLK1 data at the 6th Annual NET Conference hosted by the North American Neuroendocrine Tumor Society (NA-NETS) to be held in Charleston, South Carolina from October 4-5, 2013.

5 Oct 2013

NIH Grant to Develop New Nanotechnology for Better Cancer Treatment

UB researcher Jonathan Lovell has received a five-year, $1.9 million grant from the National Institutes of Health to work on a new nanotechnology that could greatly improve how doctors treat and understand cancer.

5 Oct 2013

MultiCell Technologies Inks New Sponsored Research Agreement for Liver Cancer Treatment

MultiCell Technologies, Inc. is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer.

4 Oct 2013

New Project to Determine Heart Attack and Stroke Risk Using Nanoparticles

A Temple bioengineer is collaborating on an NIH-funded project to develop a nanotechnology that will help doctors determine the location and severity of plaques in artery walls before they rupture.

4 Oct 2013

Nanobiosym Health RADAR Wins Top Honors at Nokia Sensing XCHALLENGE

Nanobiosym Health RADAR, a Boston-based research incubator institute led by Dr. Anita Goel, was awarded the $525,000 Grand Prize in the first competition of the Nokia Sensing XCHALLENGE for their Gene-RADAR® sensing technology that will transform the way health care is delivered by enabling personalized diagnostic testing.

4 Oct 2013

Preclinical Data Demonstrates Potent Anti-Viral Activity of TKM-Marburg Therapeutic Treatment

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced today that preclinical data demonstrating potent anti-viral activity of TKM-Marburg were presented at DIA/FDA Oligonucleotide-based Therapeutics Conference taking place in Washington, DC from September 25-27, 2013 by Tekmira's Chief Scientific Officer, Dr. Ian MacLachlan.

26 Sep 2013

Nanoparticle Vaccine Developer, Novavax to Start Pandemic and Seasonal Influenza Trials in 2014

Novavax, Inc. a clinical-stage vaccine company, announced today that it is finalizing details on costs and timelines for their next round of clinical studies with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) following successful completion of process improvement studies.

From Novavax Inc. 25 Sep 2013